Vericiguat Modulates Osteoclast Differentiation and Bone Resorption via a Balance between VASP and NF-κB Pathways

Figure 9

Validation of the effects of Vericiguat on OVX-induced bone loss in vivo indicated by microstructure analysis. (a) Representative 3-dimensional images of μCT for mouse femur from the sham group (mock operation with DMSO injection), OVX group (OVX with DMSO injection), low-dose group (OVX with low-dose Vericiguat, 5 μg/kg/day), and high-dose group (OVX with high-dose Vericiguat, 10 μg/kg/day) (). (b) Quantitative results of bone structural parameters, including trabecular bone mineral density (BMD, g/cc), bone surface area/total volume (BS/TV; %), bone volume/total volume (BV/TV; mm⁻¹), trabecular number (Tb.N; mm⁻¹), trabecular spacing (Tb.Sp; mm), and trabecular thickness (Tb.Th; mm) within the selected metaphyseal region (). (c) Representative 3-dimensional images of μCT for the mouse femur (cortical bone) from different groups above. (d) Quantitative results of bone structural parameters, including cortical bone mineral density (BMD; g/cc), bone volume/total volume (BV/TV; mm⁻¹), total cross-sectional area inside the periosteal envelope (Tt.Ar; mm²), cortical bone area (Ct.Ar; mm²), cortical area fraction (Ct.Ar/Tt. Ar; %), and average cortical thickness (Ct.Th; mm). indicated a comparison with the sham group: and . # indicated a comparison between the VEGT-L/H group and OVX group at the same concentration of Vericiguat: ^##, ^###, and ^####. ns: not statistically significant.

(a)

(b)

(c)

(d)